Latest Breaking News On - Scopus biopharma - Page 2 : comparemela.com

Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer -November 02, 2023 at 09:15 am EDT

NEW YORK, Nov. 02, 2023 Scopus BioPharma Inc. , a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary,.

Ninja Nation will bring 2 new locations to Arizona

Ninja Nation announced the lease signing of two new facilities in Glendale and Scottsdale, marking the brand’s entrance into Arizona.

Enlivex Therapeutics (NASDAQ:ENLV) vs. Scopus BioPharma (NASDAQ:SCPS) Critical Review

Enlivex Therapeutics (NASDAQ:ENLV – Get Rating) and Scopus BioPharma (NASDAQ:SCPS – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability. Profitability This table compares Enlivex Therapeutics and Scopus BioPharma’s […]

Non-Hodgkin Lymphoma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Key Companies - AbbVie, Novartis, AstraZeneca, Jiangsu Hengrui Medicine, Pacylex Pharma |

BioSig Technologies : Annual report pursuant to Section 13 and 15(d)

Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases , which amended. | March 31, 2023